- Home
- QIPT vs GALT Comparison
QIPT vs GALT Comparison
Compare QIPT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- GALT
- Stock Information
- Founded
- QIPT 1993
- GALT 2000
- Country
- QIPT United States
- GALT United States
- Employees
- QIPT N/A
- GALT N/A
- Industry
- QIPT
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- GALT Health Care
- Exchange
- QIPT Nasdaq
- GALT Nasdaq
- Market Cap
- QIPT 92.2M
- GALT 83.5M
- IPO Year
- QIPT N/A
- GALT N/A
- Fundamental
- Price
- QIPT $1.78
- GALT $2.18
- Analyst Decision
- QIPT Buy
- GALT Buy
- Analyst Count
- QIPT 2
- GALT 2
- Target Price
- QIPT $2.85
- GALT $6.00
- AVG Volume (30 Days)
- QIPT 614.3K
- GALT 1.4M
- Earning Date
- QIPT 08-13-2025
- GALT 08-12-2025
- Dividend Yield
- QIPT N/A
- GALT N/A
- EPS Growth
- QIPT N/A
- GALT N/A
- EPS
- QIPT N/A
- GALT N/A
- Revenue
- QIPT $240,848,000.00
- GALT N/A
- Revenue This Year
- QIPT $3.35
- GALT N/A
- Revenue Next Year
- QIPT $5.39
- GALT N/A
- P/E Ratio
- QIPT N/A
- GALT N/A
- Revenue Growth
- QIPT N/A
- GALT N/A
- 52 Week Low
- QIPT $1.35
- GALT $0.73
- 52 Week High
- QIPT $4.07
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- QIPT 44.77
- GALT 56.31
- Support Level
- QIPT $1.75
- GALT $2.08
- Resistance Level
- QIPT $2.18
- GALT $2.66
- Average True Range (ATR)
- QIPT 0.09
- GALT 0.53
- MACD
- QIPT -0.02
- GALT -0.02
- Stochastic Oscillator
- QIPT 17.54
- GALT 33.09
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.